Abstract
Background: The prevalence of SARS-CoV-2 coinfection in people living with HIV has not been investigated systematically. Based on several considerations it is, however, unclear if data from general populations can serve as a reference. This study aimed to determine the proportion of people living with HIV with anti-SARS-CoV-2 IgG-antibodies in a sample from a large single HIV center in Munich, Germany, after the first phase of the coronavirus pandemic and to infer about the prevalence in people living with HIV. Methods: Prospective sub-study of the ongoing ArcHIV cohort between May and July 2020. Anti-SARSCoV-2 IgG-antibodies were measured using the recomWell SARS-CoV-2 IgG ELISA (Mikrogen, Neuried, Germany). Demographic and medical data were extracted from the electronic patient files. Findings: Overall, 500 people living with HIV were included in the study (83% male, median age: 51 years). Of those, 22 were found to be positive for SARS-CoV-2 IgG antibodies (0.044), resulting in an estimated seroprevalence (considering sensitivity ans specificity of the test) of 5.1 % (CI95%: 3.17; 7.02) for the entire study sample, and 5.2 % (CI95%: 2.62; 7.69) for the subset of Munich citizens. Only two out of 22 PLWH (9.1%) with positive SARS-CoV-2 serology had previously been diagnosed with SARS-CoV-2 coinfection. The proportion of Caucasian people living with HIV was significantly smaller in the group with positive when compared to the group of negative test results (68.2% vs. 88.1%, p=0.021). Interpretation: Anti-SARS-CoV-2 antibodies are frequently found in people living with HIV. Many people are olig- or asymptomatic but probably still able to pass the infection to others. Racial disparities seem to play a role in the risk of exposure to SARS-CoV-2 even in high-income areas. Funding: Mikrogen GmbH (Neuried, Germany) provided the test kits used in this study. The funding source was not involved in any aspects of the study.Declaration of Interests: All authors declare support for the study from Mikrogen GmbH (Neuried, Germany) by providing test kits used in this study. SN reports honoraria and/or grants for research or travel from Gilead Sciences, GSK, MSD Sharp & Dohme, Hexal, Hormosan Pharma, HRA Pharma, Ipsen Pharma, Janssen-Cilag, Shire Pharmaceuticals, and ViiV Healthcare. FS reports honoraria and/or grants for research or travel from Abbvie, Gilead Sciences, Hexal, Janssen-Cilag, and MSD Sharp & Dohme. SH reports honoraria and/or grants for research or travel from Abbvie, Gilead Sciences, and Janssen-Cilag. KR reports grants for travel from Abbvie and Gilead Sciences. CJ reports honoraria and/or grants for research or travel from Abbvie, Gilead Sciences, GSK, Janssen-Cilag, and ViiV Healthcare. HJ reports honoraria and/or grants for research or travel from Abbvie, Gilead Sciences, GSK, Janssen-Cilag, and ViiV Healthcare. EW reports honoraria and/or grants for research or travel from Abbvie, Gilead Sciences, GSK, Janssen-Cilag, and ViiV Healthcare. WM, FT, AK, CW, AB, and EG have nothing else to disclose.Ethics Approval Statement: This study was performed as a prospective, cross-sectional sub-study of the Munich ArcHIV cohort, an ongoing cohort in PLWH in Munich, Germany, with approval of the local ethic’s committee dating May 28th, 2020.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.